A single, low dose of a current Good Manufacturing Practice (cGMP) recombinant BCG vaccine confers protection against human respiratory syncytial virus (hRSV) infection and lung pathology in mice

Abstract

Human respiratory syncytial virus (hRSV) is a major health burden worldwide, causing most of the hospitalizations due to bronchiolitis and pneumonia in children below the age of two years. HRSV causes year-to-year outbreaks of disease, which also affects